The pharmacist's role in enhancing adherence to GLP1 based anti-obesity medications through comprehensive side effect management
4 affiliations
- 1School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Israeli Pharmaceutical Society (PSI), Tel Aviv, Israel; Corresponding author at: School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
- 2Department of Medical Technologies, Maccabi Healthcare Services, Tel-Aviv, Israel; School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel
- 3Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center, Beilinson Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
- 4Department of Health Management and Policy, Guilford Glazer Faculty of Business and Management and Health Sciences Faculty, Ben Gurion University, Beer Sheva, Israel
Abstract
The emergence of glucagon-like peptide-1 (GLP1) and GLP1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (hereinafter GLP1-RAs, GLP1-GIP-RAs) have transformed obesity treatment. These agents offer substantial weight loss and notable cardiometabolic and other health benefits. Yet, their success relies on long-term adherence and careful management of side effects. Common adverse events – especially gastrointestinal (GI) disturbances - often lead to treatment discontinuation, weight regain and reduced effectiveness. As healthcare providers with multiple patients' interactions, pharmacists provide continuous care throughout the entire treatment journey, from initiation through titration phase and long-term maintenance. The unique position of pharmacists' interactions with patients enables them to address the high rates of non-adherence commonly observed with GLP1 based medications, which often stem from GI side effects, medication complexity, and patient education gaps. Treatment persistence and patient outcomes can be significantly improved through structured, pharmacist-led strategies, including comprehensive patient education, lifestyle modifications, and judicious use of over-the-counter interventions and vitamin/mineral/supplement therapies. Critical emphasis is placed on the pharmacist's role in preventing and managing serious complications associated with rapid weight loss, particularly sarcopenia and nutrient deficiencies, while maintaining vigilance for “red flags” that signal serious complications requiring physician intervention. This manuscript delineates the rationale for pharmacist involvement through the phases of adherence: initiation, titration, persistence, and discontinuation. It provides side-effect incidence and management tables, possible lifestyle and treatment options in each phase, red-flag and referral criteria, strategies to prevent sarcopenia and nutrient deficiency. Implementing these pharmacist-driven interventions can significantly improve tolerability, adherence, and long-term clinical outcomes in obesity pharmacotherapy.
Related
- Adherence of HIV/AIDS patients following Medication Therapy Management and Pharmacist Counselling at a Public Hospital in Yogyakarta, Indonesia
- Pharmacist-Led Comprehensive Medication Management and Patient Outcomes in Pediatric Intensive Care Unit Patients: A Multicenter Cohort Study
- A cross-sectional benchmark of seven large language models for National Comprehensive Cancer Network guideline adherence in non-small cell lung cancer management.
- Beyond words: Enhancing medication understanding with pictograph-integrated pharmacist counseling in linguistically diverse patients
- Prescribing Trends of Osteoporosis Medications, Adherence and Persistence with Denosumab versus Alendronate: A Real-World Retrospective Study in China.
BibTeX
@article{schwartzberg2026pharmacists,
title = {{The pharmacist's role in enhancing adherence to GLP1 based anti-obesity medications through comprehensive side effect management}},
author = {Eyal Schwartzberg and Carmil Azran and Talia Diker-Cohen and Segev Shani and Idit Dotan},
journal = {Exploratory Research in Clinical and Social Pharmacy},
year = {2026},
month = oct,
doi = {10.1016/j.rcsop.2026.100867},
url = {https://doi.org/10.1016/j.rcsop.2026.100867},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - The pharmacist's role in enhancing adherence to GLP1 based anti-obesity medications through comprehensive side effect management
AU - Eyal Schwartzberg
AU - Carmil Azran
AU - Talia Diker-Cohen
AU - Segev Shani
AU - Idit Dotan
PY - 2026
DA - 2026/10/20
JO - Exploratory Research in Clinical and Social Pharmacy
DO - 10.1016/j.rcsop.2026.100867
UR - https://doi.org/10.1016/j.rcsop.2026.100867
AB - The emergence of glucagon-like peptide-1 (GLP1) and GLP1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (hereinafter GLP1-RAs, GLP1-GIP-RAs) have transformed obesity treatment. These agents offer substantial weight loss and notable cardiometabolic and other health benefits. Yet, their success relies on long-term adherence and careful management of side effects. Common adverse events – especially gastrointestinal (GI) disturbances - often lead to treatment discontinuation, weight regain and reduced effectiveness. As healthcare providers with multiple patients' interactions, pharmacists provide continuous care throughout the entire treatment journey, from initiation through titration phase and long-term maintenance. The unique position of pharmacists' interactions with patients enables them to address the high rates of non-adherence commonly observed with GLP1 based medications, which often stem from GI side effects, medication complexity, and patient education gaps. Treatment persistence and patient outcomes can be significantly improved through structured, pharmacist-led strategies, including comprehensive patient education, lifestyle modifications, and judicious use of over-the-counter interventions and vitamin/mineral/supplement therapies. Critical emphasis is placed on the pharmacist's role in preventing and managing serious complications associated with rapid weight loss, particularly sarcopenia and nutrient deficiencies, while maintaining vigilance for “red flags” that signal serious complications requiring physician intervention. This manuscript delineates the rationale for pharmacist involvement through the phases of adherence: initiation, titration, persistence, and discontinuation. It provides side-effect incidence and management tables, possible lifestyle and treatment options in each phase, red-flag and referral criteria, strategies to prevent sarcopenia and nutrient deficiency. Implementing these pharmacist-driven interventions can significantly improve tolerability, adherence, and long-term clinical outcomes in obesity pharmacotherapy.
SN - 2667-2766
ER -